Investors

/Investors
Investors 2018-06-03T13:22:26+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

7.00
-0.21 (-2.91%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :37,967
Date :06-15-2018

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at the American Diabetes Association 78th Scientific Sessions

June 12th, 2018|Comments Off on Oramed to Present at the American Diabetes Association 78th Scientific Sessions

NEW YORK, June 12, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that three scientific abstracts will be [...]

Oramed Patent Allowed in the US for Oral Administration of Proteins

May 30th, 2018|Comments Off on Oramed Patent Allowed in the US for Oral Administration of Proteins

NEW YORK, May 30, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions [...]

First Oral Insulin For Diabetics Takes Major Step Towards FDA Approval

May 16th, 2018|Comments Off on First Oral Insulin For Diabetics Takes Major Step Towards FDA Approval

New York-based Oramed begins its largest clinical trial to date under FDA, recruiting type 2 diabetics across the country. New York, NY – May 16, 2018 – Oral insulin, the Holy Grail of diabetes care [...]

Oramed to Present at Conferences in May

May 7th, 2018|Comments Off on Oramed to Present at Conferences in May

NEW YORK, May 7, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present at [...]